On 18 November 2021, the Competition Appeal Tribunal (CAT) published summaries of three appeals by Mercury Pharmaceutical Limited, HG Capital LLP and Cinven (Luxo 1) S.a.r.l. against the Competition and Markets Authority (CMA). The appeals relate to the CMA’s decision that the above parties abused dominant positions by charging excessive and unfair prices with respect to the supply of 20mcg liothyronine sodium tablets in the UK. The CAT issued an order requiring the CMA to file a consolidated defence to these appeals, and gave the CMA until 14 January 2022 to do so.